Large-scale testing (Phase 3)UnknownNCT06186986What this trial is testingCD30 Imaging in Diffuse Large B-cell LymphomaWho this might be right forDiffuse Large B-cell-lymphoma University Medical Center Groningen 20
Large-scale testing (Phase 3)Study completedNCT01578499What this trial is testingTrial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)Who this might be right forPrimary Cutaneous Anaplastic Large Cell LymphomaMycosis FungoidesCutaneous T-Cell Lymphoma Millennium Pharmaceuticals, Inc. 131
Testing effectiveness (Phase 2)Active Not RecruitingNCT03113500What this trial is testingBrentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell LymphomaWho this might be right forAdult T-Cell Leukemia/LymphomaAnaplastic Large Cell Lymphoma, ALK-NegativeAnaplastic Large Cell Lymphoma, ALK-Positive+8 more City of Hope Medical Center 48
Not applicableStudy completedNCT03729609What this trial is testingDrug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"Who this might be right forUntreated CD30-Positive Hodgkin's Lymphoma Takeda 113
Not applicableStudy completedNCT05506774What this trial is testingPeople With CD30 Positive Lymphoma in ChinaWho this might be right forLymphoma Takeda 1,006
Early research (Phase 1)Study completedNCT00430846What this trial is testingPhase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic MalignanciesWho this might be right forLymphoma, Non-HodgkinDisease, HodgkinLymphoma, Large-Cell, Anaplastic Seagen Inc. 45
Early research (Phase 1)WithdrawnNCT02780011What this trial is testingAlsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid MalignanciesWho this might be right forCD30-positive LymphomaCD30-positive Solid Tumor Eric Bernicker, MD
Testing effectiveness (Phase 2)Study completedNCT03192202What this trial is testingAFM13 in Relapsed/Refractory Cutaneous LymphomasWho this might be right forLymphoma, T-Cell, Cutaneous Ahmed Sawas 18
Early research (Phase 1)Active Not RecruitingNCT04526834What this trial is testingPhase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin LymphomaWho this might be right forAnaplastic Large Cell LymphomaPeripheral T Cell LymphomaExtranodal NK/T-cell Lymphoma+2 more Tessa Therapeutics 21
Testing effectiveness (Phase 2)Ended earlyNCT05883449What this trial is testingPhase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCLWho this might be right forRelapsed or Refractory Hodgkin LymphomaPeripheral T Cell Lymphoma Affimed GmbH 25
Early research (Phase 1)Study completedNCT00048880What this trial is testingPhase I Study of HeFi-1 to Treat Cancers With CD30 ProteinWho this might be right forNeoplasms National Cancer Institute (NCI) 9
Early research (Phase 1)Study completedNCT01026415What this trial is testingClinical Pharmacology Study of Brentuximab Vedotin (SGN-35)Who this might be right forCarcinomasDisease, HodgkinLymphoma, Large-Cell, Anaplastic+2 more Seagen Inc. 73
Early research (Phase 1)Looking for participantsNCT05544968What this trial is testingAnti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic MalignanciesWho this might be right forHodgkin DiseaseCD30-Positive Diffuse Large B-Cell LymphomaCD30+ Anaplastic Large Cell Lymphoma+4 more Medical College of Wisconsin 42
Testing effectiveness (Phase 2)Looking for participantsNCT03356054What this trial is testingPhase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First RelapseWho this might be right forDLBCL Stichting Hemato-Oncologie voor Volwassenen Nederland 37
Early research (Phase 1)Looking for participantsNCT06176690What this trial is testingConstitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive LymphomasWho this might be right forCD30-Positive Diffuse Large B-Cell LymphomaAnaplastic Large Cell Lymphoma, T Cell and Null Cell TypeAnaplastic Large Cell Lymphoma, ALK-Positive+4 more Baylor College of Medicine 90
Testing effectiveness (Phase 2)Study completedNCT02388490What this trial is testingBrentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive LymphomasWho this might be right forRelapsed or Refractory EBV-and CD30-positive Lymphomas Seoul National University Hospital 25
Not applicableWithdrawnNCT01671813What this trial is testingBrentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of ElderlyWho this might be right forLymphoma H. Lee Moffitt Cancer Center and Research Institute
Not applicableLooking for participantsNCT06850285What this trial is testingCD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory LymphomaWho this might be right forLymphoma, B-Cell Shanxi Bethune Hospital 15
Very early researchNot Yet RecruitingNCT07048353What this trial is testingCD30 CAR-T in the Treatment of CD30 Positive LymphomaWho this might be right forLymphomaB Cell LymphomaCD30+ Peripheral T-cell Lymphoma Shandong Qilu Cell Therapy Engineering Technology Co., Ltd 15
Testing effectiveness (Phase 2)UnknownNCT05320081What this trial is testingCamrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ LymphomaWho this might be right forLymphomaRelapse/Recurrence Huazhong University of Science and Technology 30